New diabetes drugs and heart failure: What have we learnt?May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure 2017
Video navigation menu
- History of CV outcome trials in type 2 diabetes 01:20
- Effect of incretin-based therapies on heart failure 05:24
- Major CV outcomes trials with DPP4-inhibitors 06:10
- Major CV outcomes trials with GLP-1 receptor agonists 11:17
- Effect of GLP-1 receptor agonists on HF hospitalization 14:35
- SGLT2-inhibitors: ho do they reduce CV risk? 16:41
This lecture was part of a CME accredited symposium: Heart failure, Diabetes, and Renal Dysfunction: Time for a more unified approach held at Heart Failure 2017 in Paris.
- Emphasize heart failure as a disease in which innovation is ongoing, yielding several new agents that are soon likely to change clinical practice
- To explore mechanisms and common pathways underlying the development of cardiovascular disease and heart failure and the particular risk of patients with diabetes
- To discuss the role of anti-diabetic therapy, in particular the use of SGLT2 inhibitors, in a risk-based intervention strategy that targets glucose control and cardiovascular risk factors
- To provide an expert perspective on the role of SGLT2 inhibitors in the treatment of patients with diabetes and heart failure
- To discuss current and future strategies for practical management of heart failure and interventions to prevent cardiovascular events
Professor John McMurray is a Professor of Medical Cardiology at the University of Glasgow and Honorary Consultant Cardiologist at the Queen Elizabeth University Hospital, Glasgow.
This EBAC accredited symposium was funded by an unrestricted educational grant received from Boehringer-Ingelheim/Lilly